To optimize the production of technical-grade lithium carbonate, Remedium has partnered with a UK firm to meet the surging demand for electric vehicles.
On Monday, Remedium Lifecare Ltd., formerly Roxy Exports, announced that it has entered into a significant agreement with Angel Partners, Ltd., to acquire technology for manufacturing lithium carbonate in India. This strategic move aims to position Remedium as a critical player in the lithium-ion battery market, meeting the growing demand for electric vehicles and portable electronics.
Furthermore, Remedium Lifecare signed an annual Supply Agreement with Alfa Chemicals and Solvents, Turkey, on the same date. This agreement, set to commence in the January-March 2025 quarter, ensures a steady supply of technical-grade lithium carbonate. The supplies for the calendar year 2025, valued between USD 20-25 million, underscore the substantial scale of this partnership. This strategic move is poised to significantly boost our production capabilities and meet the increasing market demand, marking a significant step in our growth and expansion.
The agreement with Alfa Chemicals and Solvents Ltd. outlines a supply value of $1.67-$2.1 billion for 2025, further highlighting the potential impact of this partnership on Remedium’s business. This substantial investment underscores the importance of lithium carbonate in the evolving battery technology market. By securing these agreements, Remedium Lifecare Ltd. not only strengthens its market position but also contributes to the broader adoption of electric vehicles and sustainable energy solutions.
